What is remnant lipoprotein testing — is it worth getting?

Remnant lipoprotein cholesterol (measured directly as IDL-C + chylomicron remnants, or calculated as total cholesterol minus LDL-C minus HDL-C) is available on some advanced lipid panels (LabCorp NMR LipoProfile, Quest Cardio IQ) and provides additional cardiovascular risk information beyond the standard lipid panel, particularly valuable in men with elevated triglycerides where the non-LDL atherogenic particle burden is incompletely captured by standard LDL-C measurement (Varbo et al., JACC, 2020).

For most men, a standard lipid panel with the addition of ApoB and Lp(a) provides the highest clinical yield per dollar spent. Advanced panels (NMR, Ion Mobility) that quantify LDL particle size and subspecies provide additional nuance but are primarily useful for men already on statin therapy where residual cardiovascular risk despite treated LDL-C needs explanation. The cost-benefit of routine advanced lipid testing versus ApoB alone is an ongoing clinical discussion.

Honesty Scale: Promising (2) for advanced lipid panel testing in men with residual cardiovascular risk on statin therapy. Early (3) for routine advanced testing as a first-line approach.

What to do: For a first-time full cardiovascular assessment: standard fasting lipid panel + ApoB + Lp(a) + hs-CRP + fasting glucose/insulin. This combination provides the most clinically practical information. Advanced panels can be added if standard panel findings leave important questions unanswered.

For the full picture, read The ApoB/Lp(a)/Lipids Deep Dive